All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 27, 2021
Home » Blogs » BioWorld MedTech Perspectives » Patent reform in search of respect

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech / Patent

Patent reform in search of respect

Oct. 3, 2011
By Mark McCarty
No Comments

We who scribble for a living find it easy to go off on those who do not, and today's bulls-eye is on the patent reform bill recently signed into law, the America Invents Act of 2011.

One of the interesting things about H.R. 1249 is that it puts some of the fees collected by the U.S. Patent and Trademark Office in an escrow for Congress to decide whether to release to PTO. I've asked a number of people around Washington whether they think Congress can resist the temptation to write PTO an IOU and just keep the money, and almost no one has said yes. However, let us not forget that PTO's fees just went up 15%. The foxes grow bolder and the hens just grow.

However, the criticisms of the bill to follow are not authored by yours truly. They are the views of Judge Paul Michel, who appeared last week at AdvaMed 2011, sponsored by the Advanced Medical Technology Association (Washington).

Just in case you haven't followed these things, Judge Michel had a spot on the bench at the Court of Appeals for the Federal Circuit (CAFC) from 1988 'til last year and served as the chief justice of the court starting in 2004. Michel has also appeared at congressional hearings on patent reform on a number of occasions, so his views have some heft in this town.

In addressing the change from first-to-invent to first-to-file (FTF), Michel said "a lot of whats in this bill is intended to be leveraged in future negotiations" regarding harmonization between national patent offices. He said the presumption is that going with FTF "will strengthen the hand of U.S. negotiators in the future" so as to give other nations some reason to adopt our grace period of 12 months after publication in academic literature. By many accounts, this grace period may vanish under H.R. 1249 unless Congress amends the statute to restore it.

Regarding such negotiations between PTO and other patent offices, Michel said, "the idea that they're just going to roll over" is of dubious merit, adding, "I don't think it's going to happen."

"Harmonization has an inherent problem," Michel continued, noting that "the more you harmonize, the more you may be moving from an excellent system to a mediocre system," which is of little help to the economy. "There's a lot here that's masked by" such considerations, he said.

Regarding the bill's provisions for post-grant review, Michel said, "the Trojan horse is that it claims to create a high threshold" for review of a patent, but he said, "I think it's going to turn out be not so nearly high as some people think."

The post-grant review is a nine-month window that goes into effect in September 2012 and allows a patent to be challenged on nearly any grounds, at least by some accounts. "I think it's going to turn out to be not so hard" to prod PTO into granting such a review, Michel said, remarking further that one outcome may be that "every commercially significant patent " will be challenged under this new process, and those challenges could drag on.

"Its not really a one-year proceeding, it's really closer to a three-year proceeding,” Michel said, which for highly iterative technologies may prove a death sentence for the market life of that patent.

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 26.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing